Seite auswählen

British medical technology company Smith & Nephew announced on Wednesday, November 28th that it will take over Healthpoint Biotherapeutics, a US-based specialist for wound management for approx. $782m.

According to company information Healthpoint will generate a $190m revenue in 2012 with its products. The US-company based in Fort Worth (Texas) is a subsidiary of DFB Pharmaceuticals Inc. and has a staff of 460 (including 215 sales representatives). In the fiscal year that ended on December 31st, 2011 Healthpoint generated a $151m revenue and realized a profit of $11m.

Comment: For Smith & Nephew, the deal is part of making efforts at diversification. Thus, S&N pushes its planned expansion with regards to wound management. This division is accounting for 25% of the turnover and has been characterized by strong growth over the past years.

With the take-over of Healthpoint S&N has direct access to the $1bn market of bioactive wound management. That this market segment seems profitable is expressed by the purchase price of four times the expected sales (equating 18 times the earnings before income and tax).

[ilink url=“http://www.boerse-go.de/nachricht/Smith-Nephew-kauft-Healthpoint-fuer-782-Mio-USD-NEP,a2975531,b79.html“] Link to source (Börse Go)[/ilink]